

## **AMENDMENTS TO THE SPECIFICATION**

Please amend the specification as follows:

**Add the following new paragraph at the first line of the specification:**

Benefit of priority is claimed to U.S. Provisional Application Serial No. 60/085,687, to Susan A. Watson and Dov Michaeli, entitled "COMBINATION THERAPY FOR THE TREATMENT OF TUMORS," filed May 15, 1998. The subject matter of this application is incorporated by reference in its entirety.

**Replace the paragraph beginning at page 8, line 3 with the following amended paragraph:**

The anti-G17 immunogens comprise a natural or synthetic peptide fragment of the N-terminal amino acids of G17 as the immunomimic portion of the immunogen. This peptide fragment is conjugated to an immunogenic carrier such as Diphtheria toxoid (DT). In a preferred embodiment of this aspect of the invention, the anti-G17 immunogen comprises the amino-terminal amino acids of G17 from positions 1 through 9, having the amino acid sequence pyroGlu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu (SEQ ID NO: 1), conjugated to Diphtheria toxoid. Other suitable immunogenic protein carriers, include bovine serum albumin, keylimpet hemocyanin, hemocyanin and tetanus toxoid.

**Replace the paragraph beginning at page 10, line 10 with the following amended paragraph:**

The anti-G17(1-9)-DT immunogen consists of amino acid residues 1-9 of G17 linked via the carboxy-terminus to the peptide spacer SSPPPPC (SEQ ID NO.: [[1]] 2 in the Sequence Listing), which in turn is conjugated to DT. The immunogen used in these studies was made specific for rat G17 by replacing the human G17 epitope with the amino terminal 9 amino acids of rat G17, linked through a peptide spacer to diphtheria toxoid (DT). Antiserum raised by rat anti-G17(1-9)-DT was denoted as anti-rat G17 (1-9):DT.